1. Home
  2. THRD vs ALDX Comparison

THRD vs ALDX Comparison

Compare THRD & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • THRD
  • ALDX
  • Stock Information
  • Founded
  • THRD 2019
  • ALDX 2004
  • Country
  • THRD United States
  • ALDX United States
  • Employees
  • THRD N/A
  • ALDX N/A
  • Industry
  • THRD Biotechnology: Pharmaceutical Preparations
  • ALDX Biotechnology: Pharmaceutical Preparations
  • Sector
  • THRD Health Care
  • ALDX Health Care
  • Exchange
  • THRD Nasdaq
  • ALDX Nasdaq
  • Market Cap
  • THRD 335.2M
  • ALDX 304.9M
  • IPO Year
  • THRD 2022
  • ALDX 2014
  • Fundamental
  • Price
  • THRD $3.47
  • ALDX $6.69
  • Analyst Decision
  • THRD Buy
  • ALDX Strong Buy
  • Analyst Count
  • THRD 3
  • ALDX 2
  • Target Price
  • THRD $14.00
  • ALDX $10.00
  • AVG Volume (30 Days)
  • THRD 1.2M
  • ALDX 352.5K
  • Earning Date
  • THRD 03-25-2025
  • ALDX 03-06-2025
  • Dividend Yield
  • THRD N/A
  • ALDX N/A
  • EPS Growth
  • THRD N/A
  • ALDX N/A
  • EPS
  • THRD N/A
  • ALDX N/A
  • Revenue
  • THRD N/A
  • ALDX N/A
  • Revenue This Year
  • THRD N/A
  • ALDX N/A
  • Revenue Next Year
  • THRD N/A
  • ALDX N/A
  • P/E Ratio
  • THRD N/A
  • ALDX N/A
  • Revenue Growth
  • THRD N/A
  • ALDX N/A
  • 52 Week Low
  • THRD $3.18
  • ALDX $2.71
  • 52 Week High
  • THRD $16.94
  • ALDX $6.92
  • Technical
  • Relative Strength Index (RSI)
  • THRD 25.71
  • ALDX 74.28
  • Support Level
  • THRD $3.18
  • ALDX $6.49
  • Resistance Level
  • THRD $3.70
  • ALDX $6.92
  • Average True Range (ATR)
  • THRD 0.31
  • ALDX 0.31
  • MACD
  • THRD 0.10
  • ALDX 0.09
  • Stochastic Oscillator
  • THRD 13.26
  • ALDX 87.84

About THRD Third Harmonic Bio Inc.

Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.

About ALDX Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Share on Social Networks: